Am Fam Physician. 2022;105(1):online
Author disclosure: No relevant financial relationships.
Details for This Review
| Benefits | Harms |
|---|---|
| Primary outcomes | No adverse events were reported |
| No one was helped (no death from any cause or from cardiovascular disease was prevented) | |
| Secondary outcomes | |
| No one was helped (no coronary heart disease event, death from coronary heart disease, type 2 diabetes mellitus, heart attack, or stroke was prevented) |
Study Population: Randomized controlled trials of adults (no upper age limit or gender limitations) at any risk of cardiovascular disease (CVD) who were taking or not taking lipid-lowering medications; participants who were acutely ill, pregnant, or breastfeeding were excluded
Efficacy End Points: All-cause mortality, cardiovascular mortality (from myocardial infarction, stroke, or sudden cardiac death), combined cardiovascular events (cardiovascular death, cardiovascular morbidity [nonfatal myocardial infarction, angina, stroke, heart failure, peripheral vascular events, atrial fibrillation], and unplanned cardiovascular interventions); secondary outcomes included myocardial infarctions, stroke, coronary heart disease mortality, coronary heart disease events (myocardial infarction, angina, or sudden cardiac death), type 2 diabetes mellitus incidence, serum lipids and insulin sensitivity, cancer diagnoses and death, weight and body mass index, blood pressure, and quality of life (any measure)
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
